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respond to their descriptions, using data from five RCTsRandomized controlled trials (RCTs) are the most
rigorous study design to evaluate health-care interventions
[1]. However, their success relies on patient recruitment,
and this can be challenging [2]. Randomization or random
allocation has been defined as: the process of assigning trial
participants to treatment or control groups using an element
of chance to determine the assignments to reduce bias (p.7)
[3]. Research has indicated that the concept of randomization
is difficult to communicate [4] and that patients can find it
challenging to understand [5,6]. Linked to this, it has been
suggested that failure to accept randomization is a major
reason for patients declining to participate in RCTs [7].
Guidelines for good clinical practice state that patients
must be informed about the purpose of the trial, the treat-
ment options, randomization, and the right to withdraw
[8]. Guidance from the UK Health Research Authority
(HRA) is available on how to describe randomization in pa-
tient information leaflets and recommends that the
following points should be explained to patients: the reason
for randomizing, that treatment will not be allocated in line
with usual clinical decision-making, that treatment will be
randomly allocated, and that neither the patient nor the doc-
tor will decide the allocated treatment. In the guidance, it
suggests that this process is ‘‘akin to drawing lots, tossing
a coin, or rolling a die’’, although specific details about
the patient may be used to ensure groups in the trial are
as similar as possible and that the patient is just as likely
to receive either/any of the study arms [9].
Much of the research to date has reported on patients’
difficulties with understanding randomization via self-
reported questionnaires [10], or interview data completed
post hoc, based on their responses to hypothetical scenarios
[11,12]. Relatively, little research has examined what re-
cruiters actually say about randomization during recruit-
ment appointments with some exceptions [13,14], and
patients’ responses are even less commonly reported. The
QuinteT Recruitment Intervention (QRI) [15] has demon-
strated the benefit of investigating what is actually said dur-
ing recruitment appointments [16,17]. The QRI is an
established recruitment intervention that includes a review
and analysis of screening and recruitment data, interviews
with recruiting clinicians, and audio recordings of consulta-
tions with patients where trial information is discussed.
Thereafter, an action plan, typically in the form of support
and specific training to help improve recruitment, is dis-
cussed and agreed with the Chief Investigator of the
RCT. The aim of the QRI is to improve information deliv-
ery and increase participant recruitment and informed con-
sent. This article is derived from the QRI research program
and investigated how recruiters and patients discussed
randomization in recruitment appointments. The findings
illuminated the reasons why patients find the concept
difficult to understand and identified opportunities for
improvement. This article presents how randomization iswith actual or anticipated recruitment difficulties.2. Method
2.1. Sampling
Data were taken from RCTs that included a QRI to support
recruitment. For this analysis, data were available from five
trials, all experiencing, or anticipated to have, recruitment dif-
ficulties. They included a wide range of specialisms (e.g., or-
thopedics, oncology, and general surgery), types of trials (e.g.,
surgery vs. nonsurgery vs. sham surgery, chemotherapy vs.
surveillance, and two- or three-arm trials), and recruiters (sur-
geons, oncologists, research nurses [RNs], and physiothera-
pists). The analysis included all available recorded
appointments from the five trials. The recordings were all
made before the RCT receiving any feedback or training
related to the recruitment intervention. Clinicians and patients
were aware that the purpose of undertaking audio recording
was to assist with trial recruitment and to improve information
delivery. In total, 73 recruitment appointments, with 56
different patients and 27 different recruiters across five RCTs
were audio-recorded. Recordings took place between 2010
and 2014. The QRI element of the studies was approved as
part of the main trial Research Ethics Committee application
in trials 1, 3, 4, and 5 and as a separate Research Ethics
Committee application for trial 2.
Table 1 provides summary information of the participating
trials and the range of recruiters providing information.2.2. Data analysis
The qualitative analysis software package NVivo 10
(QSR international) was used to support data storage and
analysis. M.J. listened to all of the recordings, following
an approach of content analysis, and screened them to iden-
tify any discussion related to randomization. All references
to randomization were extracted, transcribed, and coded.
Documentation was also done where there was no reference
to randomization. In keeping with Jenkins’ analysis [18],
we included explicit mentions of randomization, for
example, where the word ‘‘randomization’’ or phrase
‘‘randomly allocated’’ was used as well as implicit men-
tions, for example, ‘‘you’ll be allocated to either treatment
x or treatment y’’. D.E. and C.C. listened and independently
coded a subset of 12 recordings. M.J., C.C., and D.E. met to
compare coding and interpretation. Differing interpreta-
tions were discussed and resolved. The data presented in
this article are transcribed excerpts from these consultations
that provided an insight into what recruiters actually said to
patients about randomization and also how patients re-
sponded. To preserve recruiters’ anonymity, individual
and trial identifiers have not been included. However, the
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Key findings
 Recruiters found it difficult to explain randomization
clearly to potential randomized clinical trial partici-
pants, using gambling-related metaphors to explain
the element of chance or relying on implied agency
in decision-making, for example, using a computer.
 Patients’ responses were mostly indicative of lack
of engagement but sometimes signaled discomfort
and misunderstanding.
 Clear explanations of the rationale for randomiza-
tion tended to occur only in response to patient-
initiated requests.
What this adds to what is known?
 Clinical staff (doctors and nurses) need support and
training to describe randomization.
 The use of gambling-related metaphors and computer
agency in RCT discussion should be discouraged.
What is the implication and what should change
now?
 Clinical staff (doctors and nurses) need support and
training to describe randomization, and use of
gambling-related metaphors and computer agency
should be discouraged.
excerpts presented are drawn from across all of the trials
and were common in each trial.
3. Results
Information about randomization was presented to pa-
tients in various ways in the trials. In all cases, patients
met at least two clinicians. In trials 1 and 2, information
M. Jepson et al. / Journal of CliTable 1. RCT details and associated number of appointments recorded
RCT id Clinical specialty RCT comparison groups
1 Orthopedics Group 1: Arthroscopy with surgical manipulat
Group 2: Arthroscopy alone
Group 3: Monitoring with specialist reassessm
2 Vascular medicine Group 1: Surgical treatment
Group 2: Stenting
3 Oncology Group 1: Adjuvant treatment
Group 2: Surveillance (with treatment offered
of cancer recurrence, if appropriate)
4 Oncology/surgery Group 1: Neoadjuvant treatment and surgery
Group 2: Definitive non-surgical treatment
5 Oncology Group 1: Adjuvant treatment
Group 2: Prognostic test-directed adjuvant tre
Totalwas first given to the patient by the relevant clinical
specialist (often the principal investigator at the center)
and thereafter further discussed with a RN in a separate
encounter. In trial 3, patients had individual appointments
with one specialist clinician and then with another. In trials
4 and 5, appointments were usually held with a clinician
and RN present at the same time.
In three of the 73 recordings, the patient was identified as
ineligible for the trial early in the appointment, making
further discussion of the trial or randomization inappropriate;
these recordings were excluded from further analysis. In
seven of the remaining 70 consultations, there was no refer-
ence to randomization, with no clear reason for that informa-
tion to be missing. None of the patients in these seven
recordings chose to participate in their respective RCT.
Thematic analysis of the remaining 63 recordings revealed
that there were three components to recruiters’ randomization
descriptions. Specifically, their descriptions covered the
method of allocation, the process of allocation, and the rea-
sons for randomization. Details of the trials and the number
of consultations reviewed from each are shown in Table 1.3.1. Method of allocation
Recruiters’ first mention of any aspect of randomization
often took the form of a description of the method of allo-
cation (see Box 1). At its most basic level, this would sim-
ply be a statement of fact, without further explanation of
how treatment would be allocated. This type of statement
occurred in seven consultations. Recruiters regularly
described the method of allocation in this manner although
the effect of this was difficult to discern given the lack of
response from patients in general. Typically, descriptions
of the method of allocation followed presentation of details
about the trial arms and included a brief mention of the
percentage chance of receiving each trial treatment. The
percentage chance of being allocated to one or another of
the treatment arms was also referred to in trials with two
arms. In some consultations, the concept of randomization
was indicated to be ‘‘complex’’ or ‘‘quite complicated’’.Number of recordings
(unique patients)
Appointment with
Doctor Nurse Joint appointment
ion
ent
16 (16) 12 4 0
8 (8) 5 3 0
on signs
17 (13) 16 0 1
16 (9) 11 0 5
atment
16 (10) 7 2 7
73 (56 patients) 51 9 13
Box 1 Descriptions of the method of allocation
Example 1.
 Research nurse: It’s what we call a randomized
control trial.
 Doctor: [Trial name] is a randomized study.
Example 2.
 Research nurse: Basically, randomisation means
that one of those three things will happen so, in
order for us to randomize you for the trial then
you know that one of those options, you know,
may happen and there is a 33% chance [of each].
Example 3.
 Doctor: Now, a few more things about [Trial 5].
It’s a randomized study so that means that 50%
of [people] who are in the study get the standard
treatment, and 50% get [trial arm 2].
Example 4.
 Doctor: It’s a fifty-fifty decision as to whether you
get [treatment name] or not and that’s not a deci-
sion we make, that’s a, sort of through a random-
isation process.
Box 2 Descriptions of the process of allocation
Example 1.
 Doctor: Essentially, we don’t decide which treat-
ment it is, but we let the computer decide because
we’re not sure whether one treatment is better than
the other.
 Research nurse: It’s done by a computer. They
make the decision as to which one you do.
Example 2.
 Patient: Yeah, but putting in the machine, some-
times the machine can tell you better than what
you can tell yourself.
 Relative: Well, like you say . the computer’s
going to come up with the best scenario for you
so you can move from there.
Example 3.
 Doctor: So that’s the situation that, that I want you
to concentrate on is that there are two treatments
you can go into. and the study will decide which
you get.
Example 4.
 Doctor: And what we do is we take a large group
of patients . and effectively toss a coin, we don’t
actually toss a coin, but effectively toss a coin, if it
comes up heads you get [Treatment 1], if it comes
up tails you don’t.
Example 5.
 Research nurse: It’s pot luck. A toss of a coin so to
speak.
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We defined the process of allocation as the means by
which patients would be allocated to trial treatment arms.
Some discussion about the process of allocation featured in
33 consultations. There were two dominant, contrasting ways
in which this was done. The most common (n 5 19) was a
description that implied there was some agency to how a de-
cision would be made about treatment allocation. The major-
ity of these (n 5 15) recruiters stated that a computer would
be involved in the decision-making process (see Box 2).
While it might be argued that what these recruiters were
describing was broadly accurate, this approach could lead
patients to believe that they would receive a form of treat-
ment that was chosen as being ‘‘best for them’’ based on
some or all of their personal characteristics, and evidence
of this interpretation was found in patient responses:
 Doctor: If you were to choose to go into the trial we
would then basically, they have a computer which,
which chooses which treatment arm you go into and
so, so there’s that, that is exactly that.
 Patient: And is that going on like your symptoms of
what you’ve had?
Immediately following this question, the recruiter at-
tempted to clarify the apparent misunderstanding, explain-
ing the ‘‘random’’ nature of the computer’s decision:
 Doctor: half patients get it, half of them don’t .
there are a few factors they take into considerationto make that the, there are, you know, that, that there
aren’t equal numbers of certain types of patients but
there’s no, you know it’s not chosen based on any
particular characteristics. It is a random choice.
This misconception was not uncommon, and in six other
consultations, patients, or their relatives, expressed a belief
that the computer would be better at deciding what was best
for them (see Box 2).
There was also evidence of recruiters apologizing for the
use of a computer as part of the allocation process, suggest-
ing discomfort on their part:
 RN: .that’s [the random allocation] done by-it
sounds terrible but by a computer system. But it’s
all set up by the statisticians.
In a further four consultations, the decision-making pro-
cess was framed in a way that gave agency to the study or
trial.
This approach generated the same misconceptions as
those that gave agency to the computer. Shortly after the
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some time to think about the decision and discuss it with
family members and a RN. After a short exchange in which
the RN stated that the patient was free to decline if she
wished, the patient’s response shows that she had misunder-
stood the ‘‘random’’ nature of allocation, and she believed
that ‘‘the study’’ would choose the best treatment for her:
 Patient: .I would rather go into the study . [it].
knows which one is best for me.
In this instance, the RN responded to this misapprehen-
sion and immediately clarified that the RCT (or ‘‘study’’)
would not be picking what was best for the patient, but
rather that the decision would be made by the ‘‘flick of a
coin’’. (RN).
This example introduces the second theme commonly
observed in descriptions of the process of allocation; re-
cruiters focusing on the ‘‘chance’’ element of how the allo-
cation would be determined. In contrast to the previous
articulation, this implied a lack of agency. These examples
were less common but still featured in 14 of the 60 consul-
tations that mentioned randomization.
The following examples typify how chance and the lack
of agency were presented to patients potentially eligible for
a two-arm trial:
 Doctor: So, the way it works is very simple. So, 50%
of [patients] who join [trial name] at random are
given [treatment 1]etoss of the coin.
 RN: .if you try and put it in simple terms it’s liter-
ally the flick of a coin, on one side you’ve got [treat-
ment 1], on the other side you’ve got [treatment 2].
We think they’re equal so we can’t make a choice
so we go like that.
In both cases, the recruiter used a metaphor to describe
the process of allocation, and in both cases, stated that there
would be no consideration of patient factors in how the
treatments were to be allocated. Yet, the process is not
‘‘literally’’ the flick of a coin, but rather certain factors will
be taken into account to ensure patient groups in the two
arms of the trial are comparable in terms of age or other
key variables. A similar approach was also observed in
several other consultations.
Across the data set, there were 15 instances of recruiters
describing the chance nature of how allocation would be
determined using these and other types of gambling meta-
phor, for instance allocation being likened to the ‘‘roll of a
dice’’, or patients being told to view allocation as something:
‘‘like a lottery’’, or by having names drawn from a hat:
 Doctor: If you say that you were happy to go to trial
at this point, you say, ‘‘I don’t know which to go-I’ll
go into a trial.’’dyour name is drawn out of a hat as
to which of those two options you will have.
Often patients did not say anything in response to these
types of descriptions, other than to simply acknowledgewhat they had been told. However, where they did respond,
these were all indicative of discomfort on their part. For
example, in this short extract, a patient responded to a
mention of a decision being made randomly in a startled
manner:
 Doctor: We would just decide randomly.
 Patient: Oh crikey.
Presenting information in this way could lead to confu-
sion and distress as well as discomfort:
 Patient: You wonder why. Why’s all this happening?
If it’s a trial and it’s a flip of a coin to which group
err come on, y’know (laughing voice) this is my life.
This response is illuminating, in that it suggests that for
this patient the use of a metaphor was problematic and
perhaps even irreverent in the context. Ultimately, this pa-
tient declined to take part in the RCT. There was also evi-
dence to suggest that recruiters anticipated that a random
selection process would be undesirable to patients:
 Doctor: the only way to decide is to-pick a name out
of a hat. And people do often think err-well they don’t
like it.3.3. The reason for randomization
Discussions about the reason for a random allocation
were notably lacking in all but 18 of the consultations.
In six of those 18, recruiters referred back to reasons
why there was a randomized study, but this focused broadly
on why the trial itself was taking place rather than on why
randomization was necessary; recruiters spoke about there
being a lack of available evidence for the RCT treatment(s)
and made passing reference to random allocation in this
context (see Box 3).
Within these descriptions, there were occasional refer-
ences to randomization being used as a means of ensuring
the fairness of the process. These excerpts explained the
reason for there being a randomized study but failed to
make a connection to the need to compare outcomes across
groups of people that were the same except for the treat-
ment received.
In the remaining 12 consultations where the reason for
randomization was described, recruiters described it as be-
ing a method of ensuring that there was no bias in the se-
lection process. In each of these cases, it was described
in a relatively succinct way, but there was no explanation
of how randomization prevented bias or indeed of what bias
meant in this context:
 RN: It [randomization] is done to make sure that it’s
kind of an unbiased result.
It was interesting to note that although patient involve-
ment in discussions about the method and process of allo-
cation was minimal, discussions about the reason for
Box 3 Descriptions of the reason for
randomisation
Example 1.
 Doctor: The trial that we’re running is actually
asking the question [about the best form of treat-
ment]. and to answer that question what we need
to do is take a large number or patients . and
randomly allocate those patients into two groups.
Example 2.
 Doctor: The reason we do a randomized study [is]
it’s the only fair way of actually comparing two
groups of patients.
Example 3.
 Research nurse: [this is] how actually most medical
studies are done . with this random allocation.
to make it a fair study.
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tion from a patient or their relative. In response to such a
question, the following recruiter provided an explanation
that captured the rationale for randomization, which was
then accepted by the patient:
 RN: Well, it’s so that they have a group of [patients]
where there’s no way of there being bias or choosing
in it. . They’re comparing [people] who are other-
wise exactly the same going into the trial.
 Patient: Yes I get it, I get that (RN).
In another consultation with the same recruiter, the pa-
tient’s partner demonstrated their understanding of the
explanation:
 Relative: So you’re trying to take the bias out of this
aren’t you by having a random study.
In a further example, a patient responded to a description
of the allocation being made by chance, by asking for
clarification:
 RN: One of the conditions of the study is you have to
be prepared to be randomly assigned to treatment.
 Patient: Why is that? Because if some people want
[treatment 1] and some people [treatment 2] why
aren’t they put into the two separate pots and the
remainder are dealt with randomly.
The patient had previously been told that treatment allo-
cation was done ‘‘totally at random’’. The recruiter subse-
quently explained that the only fair way to run a trial was
for patients to be randomly allocated to treatment arms to
avoid any bias:
 RN: We need to make sure that if there turns out to be
a difference between those two different pots one wayor the other . one pot does better or worse than the
other one then we have to be sure that the reason for
that difference is because we’ve done different things
to the two different groups of people (RN).
.
 Patient: I can understand that logic better now.
The patient was satisfied with this explanation and con-
sented to being randomized. However, explanations such as
this were rarely present.
One recruiter had developed an approach of describing
the reason for randomization which focused on the balance
between the two groups of patients and used a similar form
of words in each of the four recorded consultations:
 Doctor: [we have two groups of patients] .that
should have the same number of men, the same num-
ber of women, the number [with worse disease]. of
[less disease] etcetera, so the only difference between
those two groups of patients is that one has had [treat-
ment 1] and one group hasn’t.4. Discussion
In this article, we have explored how the process of
random allocation is described and discussed in RCT
recruitment appointments. Recruiters communicated two
levels of difficulty in presenting information about random-
ization: first, an assumption that patients would dislike the
concept of randomization as a means to determine treat-
ment, and second that they would struggle to understand
the meaning of a ‘‘randomized study’’ or the concept or
purpose of randomization more specifically. They commu-
nicated their discomfort by stating that allocation was
random that it was generally a complex process, or in some
case, by not providing an explanation of randomization at
all. When recruiters talked about the process of allocation,
they often used metaphors related to chance (usually
gambling) as part of their descriptions or referred to a com-
puter or the RCT having agency over how allocation would
be made. There was evidence from patient responses that
these approaches were problematic and detrimental to pa-
tient understanding. We also noted that recruiters included
the purpose or rationale for randomization much less often
than the process and usually only in response to questions
generated by patients.
Much of what is known empirically about how random-
ization is discussed is based on hypothetical situations [19],
with members of the public who do not have the same level
of investment in the information as they would if they were
trial-eligible patients. Where the views of patients have
been sought, they are not usually related to recruitment in
a specific trial, rather just about generic information and
overall understanding of randomization among the key con-
cepts of RCTs [20]. In contrast, in this article, we
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RCTs went about explaining randomization to patients
who were eligible for the respective RCTs and how patients
responded to these explanations.
It has been suggested that the concept of randomisation
is difficult to communicate [3]. Furthermore, patients can
find the concept of randomisation to be challenging to un-
derstand [4,21,22] and that patients may not be prepared to
be randomized to a trial if other options are available to
them [23]. In our analysis, we saw recruiters describing
the method of allocation in a relatively straightforward
manner, usually referring to the percentage chance of a pa-
tient being allocated to one or other of the treatment arms.
The approaches taken by many recruiters in describing this
process of allocation, however, were often problematic. Re-
cruiters commonly made references to a decision being
made with some agency, with several making reference to
the involvement of a computer or the study as part of the
process of allocating treatment arms. The literature about
descriptions of randomisation presents mixed views of the
implications of referring to a computer in this context.
For example, a focus group study reported patient anxiety
about the de-personalization of the allocation process if un-
dertaken by a computer [14]. In contrast, when members of
the public and patients attending oncology outpatient
clinics were asked to select their preferred description of
the randomisation process from a list of seven alternatives
[17], one of the most selected options was the following:
A computer will randomly allocate you to one of two
possible methods of treatment. Perhaps, the problem is
not about reference to a computer per se but rather that pa-
tients are misinterpreting the role of the computer as
providing some agency to the decision-making about their
treatment allocation. This then creates an associated misun-
derstanding about the role of ‘‘the computer’’ in the
decision-making process [24]. Lidz et al. [25] suggest that
where patients were told that their treatment was decided
by a computer, their ‘‘personal frame’’ led them to believe
that they would receive a treatment designed for them.
Given that patients have stated that they prefer it when their
doctor makes decisions about their treatment allocation
[26], it is likely that recruiters’ reference to computer-
aided decision-making provides a proxy for the doctor’s
expertise. Thus, perhaps unwittingly, by invoking a ‘‘com-
puter’’ as the decision-making tool, recruiters are distanced
from the potentially discomforting discussion with patients
where they must acknowledge that there is uncertainty as to
the best form of treatment. However, a problem with
creating an impression that some decision-making agency
exists is that it leads some patients to believe they will
receive the best form of treatment for themda therapeutic
misconception [5,27]. The problems associated with a ther-
apeutic misconception include that patients end up with un-
realistic optimism about the treatment they will receive
being best fitted to their condition [28] as well as not being
clearly informed about the justification for the trial. In thewider context, it perhaps reinforces the notion that patients
may interpret the offer of trial participation as a ‘‘personal
recommendation’’ from the clinician [29].
We observed recruiters using a range of metaphors to
describe the chance nature of treatment allocation. Most
of these were related to ‘‘gambling’’ in some way. For
example, the roll of a dice, toss of a coin, or drawing lots.
Metaphor has been previously reported as a component of
recruiters’ explanations [30] and often reported as being
unpopular among patients. For example, gambling-related
metaphors, such as drawing names from a hat, were dis-
liked in focus group discussions with patients because of
perceived associated risks to their lives [31]. Similarly, in
an interview-based study with members of the public and
staff and students at a medical school, the least preferred
description of randomisation was reported to be one that
referred to a coin being tossed [11], with some members
of the public stating that they would not allow a treatment
allocation to be made in that manner. However, where re-
cordings of consultations had previously been coded, coin
toss metaphors were one of the most commonly used
phrases by clinicians [19]. This type of metaphor was also
the most common in our data and identified as problematic
by patients. Krieger [31] summarizes the problem of a coin
toss metaphor as one which may lead patients to believe
that they might ‘‘win’’ or ‘‘lose’’ in the randomisation pro-
cess’’ according to the way the coin lands (2014: 1,171).
So, while metaphors may be a convenient way for re-
cruiters to describe an unfamiliar concept (randomisation),
linking it with a familiar concept associated with chance
(gambling) appears to be flawed. The evidence in this
article suggests that the use of such metaphors is still prev-
alent, and it remains recommended in the UK HRA guid-
ance. These findings suggest that there is sufficient
evidence to advise against the use of gambling-type
metaphors.
Several studies report that the purpose of random alloca-
tion is poorly understood by patients [27,32]. This article
provides insight into why understanding may be poor: ex-
planations of the purpose or rationale for randomisation
are largely absent. Our findings align with those of Brown
et al. [33]din an observational study of oncology trial dis-
cussions, under half of 59 recordings of patient consulta-
tions featured information about the reason for
randomisation. In our data, where such descriptions were
present, they had often been initiated by patient questions
rather offered by recruiters themselves. A clear implication
of the rationale being either absent or poorly explained is
that patients may not understand why they are being ran-
domized. Managing patients’ lack of understanding and/
or acceptance of being randomly allocated to one or
another treatment option adds to the emotional burden of
discussing trials with patients [34]. Hence, offering clear
explanations of why randomisation is happening could go
some way to reducing that emotional burden, while also
ensuring patients’ decision-making about trial participation
82 M. Jepson et al. / Journal of Clinical Epidemiology 99 (2018) 75e83is better informed. We also found consultations where there
was no mention of randomisation, and unsurprisingly, these
patients were not recruited. In terms of improving trial
recruitment, it has been reported that where more informa-
tion is provided about the logic for a trial, patients who
were previously uneasy about being randomized can
change their mind [35]. It has been reported that training
for those engaged in recruitment to RCTs can increase con-
fidence in presenting concepts such as randomisation to pa-
tients [36], and this has been demonstrated in RCTs with
embedded qualitative work [37].5. Conclusions
This article provides a further demonstration of what
qualitative research can bring to RCTs and their recruitment
[38e40]. By examining the detail of what was said in actual
consultations, we have been able to turn an empirical lens on
concepts that to date have primarily been based on theoret-
ical interpretations or post hoc analysis of the reported data.
The way recruiters in these RCTs commonly tended to
describe randomisation was often detrimental to patient
recruitment and informed consent. There is clear evidence
that recruiters should avoid problematic gambling metaphors
and illusions of agency in their explanations and instead
focus on clearer descriptions of the rationale and method
of randomisation to enable patients to better understand this
crucial part of the recruitment and informed consent process.Acknowledgments
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